Symyx Board Rejects Certara Bid, Favors Accelrys Deal

Symyx's board has decided that Certara's recently lowered bid is not superior to the initial agreement Symyx signed to merge with Accelrys.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories